BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, May 28, 2026
View BioWorld MedTech
Home » Ophthalmic Sciences eyes 2023 for launch of AI device for glaucoma
To read the full article sign up for free or sign in.

Ophthalmic Sciences eyes 2023 for launch of AI device for glaucoma

Dec. 6, 2021
By Catherine Longworth
Israeli startup Ophthalmic Sciences Ltd. is targeting 2023 for regulatory clearance of its artificial intelligence (AI)-based contactless intraocular pressure (IOP) measuring device, IO Perfect. The technology, which combines AI visual analysis in a virtual reality headset, enables remote monitoring of glaucoma. The device is designed to be used at home, in eye clinics, emergency room departments, pharmacies and primary physician settings.
Medical technology Newco news Diagnostics Artificial intelligence Digital health Telehealth Ophthalmic Middle East North Africa

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 27, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 26, 2026
  • Microscopy of a cross-section of mouse skin containing melanoma tumors

    Researchers identify innate immune barrier against melanoma

    BioWorld
    Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
  • In the clinic for May 26, 2026

    BioWorld
    Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...
  • Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers

    BioWorld Science
    Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing